Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of doxorubicin + cyclophosphamide + vindesine with valproic acid in refractory or relapsed small cell lung cancer
2008-004278-41Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Jul 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, cyclophosphamide, vindesine and valproic acid in small cell lung cancer (SCLC), sponsored by Institut Jules Bordet. Primary endpoint: 6-month progression-free survival. Started Jul 2008; status: completed.
02
Drugs
doxorubicincyclophosphamidevindesinevalproic acid
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2008-004278-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004278-41.